Biologic Development Image

Management

Kirtland Poss, President & CEO

Mr. Poss is co-founder, President and CEO of BioAnalytix. Previously, Mr. Poss founded and ran the molecular imaging company VisEn Medical as President and CEO from its early technology platform formation in 2000 through product development, worldwide commercialization, pharmaceutical partnerships, and M&A with PerkinElmer in 2010. In his role with VisEn, Mr. Poss led the development, launch and commercialization of multiple molecular imaging system and agent product lines, and also ran several of VisEn’s strategic partnerships with leading pharmaceutical companies and clinical research centers in applying VisEn’s molecular imaging agents in pharmaceutical development pipelines and clinical trials. Before VisEn, Mr. Poss worked in healthcare business strategy consulting for Kendall Strategies in Cambridge, MA, and prior to that he worked in scientific research at the Center for Molecular Imaging Research at the Massachusetts General Hospital and Harvard Medical School. He is a co-author on several scientific publications and multiple patents in the fields of biomarker imaging and pharmaceutical development.

Shiaw-Lin (Billy) Wu, PhD, Chief Scientific Officer

Dr. Wu is Chief Scientific Officer of BioAnalytix. Dr. Wu developed his expertise in advanced analytics and biologic drug development with Genentech, where he spent nine years in areas of protein chemistry and advanced analytical methods for complex characterizations of biologic pharmaceuticals. After that, he further developed his analytic expertise with ThermoFisher Scientific where he worked in developing methods and applications of hybrid mass spectrometry in proteomics. During his time at the Barnett Institute, Dr. Wu focused on various advanced analytical techniques and methods for complex protein analysis and biologic drug characterization, including ETD for complicated disulfide characterization, LC-MS for biosimilar comparison mapping, and protein PK/PD characterization analyses using unique sample preparation techniques combined with hybrid mass spectrometry. Dr. Wu’s primary focus has been in applying these advanced analytical approaches in biologic drug development and regulatory strategies with multiple pharmaceutical and biotechnology companies in the US and abroad. He has published more than 70 scientific papers in these areas.

Jennifer S. (Laurence) Chadwick, PhD, Director of Biologic Development

Dr. Chadwick is Director of Biologic Development at BioAnalytix. Prior to joining BioAnalytix, Dr. Chadwick was a tenured Professor and Louise Byrd Graduate Educator in the Department of Pharmaceutical Chemistry at the University of Kansas. She is an expert in the analysis of proteins, and her academic research focused particularly on understanding the molecular mechanisms underlying instability of proteins and their stabilization by exogenous compounds. During her twelve years at KU, Prof. Chadwick also collaborated and consulted with numerous pharma/biotech companies to investigate stability problems and related formulations in therapeutic proteins, including monoclonal antibodies and antibody drug conjugates (ADCs), and she is an invited member of the Higher Order Structure (HOS) consortium. Her academic work spanned a diverse set of research problems, including biomaterials, and has resulted in over 50 peer-reviewed publications, 13 patents and 4 book chapters. Dr. Chadwick is an Editorial Advisory Board member for Journal of Pharmaceutical Sciences and Scientific Reports. She received her PhD form Purdue University, Department of Chemistry for her quantitative analysis of interactions between chemokines and a diverse set of partner molecules.

Lily Li, PhD, Senior Director of Lab Process and Platform Development

Dr. Li is Sr Director of Process and Platform Development of BioAnalytix. Previously Dr. Li was Laboratory Director at Tandem Labs and prior to that she was Head of PharmaKD, which was acquired by Tandem Labs. While at Tandem Labs, Dr. Li built proprietary platforms along with QA/QC processes to support pharmaceutical research and development from early discovery to clinical development. Before joining PharmaKD/Tandem, Dr. Li was the Director of Analytics, Mass Spectrometry and the Founding Scientist, where she developed innovative analytic platforms and set up a QA/QC process to be qualified as a CLIA certified laboratory. As Head of High Throughput Analytics at Monsanto, she was responsible for the development of biochemical profiling platforms which were used to support Monsanto company-wide Genomics pipeline and Biotech research projects. Dr. Li is a co-author on several patents in methods and process of small and large molecules analysis. Dr. Li was an NIH post-doctoral fellow in Drug Testing and Toxicology and received her Ph.D. in Food Chemistry at Cornell University. She earned her M.S. in Nutritional Biochemistry at University of Illinois, Urbana-Champaign.

Wael Yared, PhD, Chief Technology Officer & VP Corporate Development

As Chief Technology Officer and Vice President of Corporate Development at BioAnalytix, Dr. Yared leads the development of the Company’s IT-driven workflows, advanced data analysis platforms and biologic informatics solutions. Previously, Dr. Yared led all product, software and platform development for PerkinElmer’s Life Sciences & Technology division and was founding director of the Company’s Center for Personalized Health Innovation. In this position, he oversaw R&D teams in the fields of imaging, microfluidics and automation for all hardware, software and reagent development activities across multiple sites in the US and Europe. Prior to this role, Dr. Yared was Chief Technology Officer for VisEn Medical, acquired by Perkin Elmer in August 2010, where he led the development of quantitative fluorescence molecular tomography systems and molecular agent portfolios. Dr. Yared holds a PhD from the Massachusetts Institute of Technology, and is a named inventor and author on a number of patents and publications.

John Ziolkowski, Chief Financial Officer

Mr. Ziolkowski is Chief Financial Officer at BioAnalytix. He brings more than 20 years of financial and operational management experience to BioAnalytix. Most recently, he served as CFO of SiOnyx, a CMOS image sensor company. Prior to SiOnyx, John was CFO at VisEn Medical, a leading biomarker imaging company acquired by PerkinElmer in 2010. In these roles, John oversaw all aspects of finance, operations, IT, legal compliance and human resource management. Previously, Mr. Ziolkowski served as CFO at Axsun Technologies, a market-leading optoelectronic instrumentation manufacturer. Mr. Ziolkowski joined Axsun from PricewaterhouseCoopers LLP, where he advised a cross section of public and private technology companies as a manager in the Technology Practice of the Audit and Business Advisory Services Group. Mr. Ziolkowski holds a B.A. in Economics/Accounting from the College of the Holy Cross and is also a Certified Public Accountant.

Back to top